Evidence map›Paper›PMID 30261931›Full record

ArticleBMC cancer2018

Data mining of digitized health records in a resource-constrained setting reveals that timely immunophenotyping is associated with improved breast cancer outcomes.

Arturo López-Pineda, Mario F Rodríguez-Moran, Cleto Álvarez-Aguilar, Sarah M Fuentes Valle, Román Acosta-Rosales, Ami S Bhatt, Shruti N Sheth, Carlos D Bustamante

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Arturo López-PinedaDepartment of Biomedical Data Science, School of Medicine, Stanford University, 1265 Welch Road, Stanford, California, 94305, USA. arturolp@stanford.edu.ORCID http://orcid.org/0000-0002-3409-1815
Mario F Rodríguez-MoranFacultad de Ciencias Médicas y Biológicas "Dr. Ignacio Chávez", Universidad Michoacana de San Nicolás de Hidalgo, Av. Dr. Rafael Carrillo S/N, Esq. Dr. Salvador González Herrejón, Morelia, 58020, Michoacán, Mexico.ORCID http://orcid.org/0000-0001-9790-1048
Cleto Álvarez-AguilarFacultad de Ciencias Médicas y Biológicas "Dr. Ignacio Chávez", Universidad Michoacana de San Nicolás de Hidalgo, Av. Dr. Rafael Carrillo S/N, Esq. Dr. Salvador González Herrejón, Morelia, 58020, Michoacán, Mexico.ORCID http://orcid.org/0000-0003-1206-6659
Sarah M Fuentes ValleHospital General Regional No. 1, Servicio de Ginecobstetricia, Instituto Mexicano del Seguro Social, Bosques de los Olivos No. 101, Charo, 61303, Michoacán, Mexico.ORCID http://orcid.org/0000-0002-8571-9537
Román Acosta-RosalesDelegación Michoacán, Instituto Mexicano del Seguro Social, Av. Madero Poniente No. 1200, Morelia, 58000, Michoacán, Mexico.
Ami S BhattDepartment of Genetics, School of Medicine, Stanford University, 300 Pasteur Drive, Stanford, 94305, California, USA.ORCID http://orcid.org/0000-0001-8099-2975
Shruti N ShethDepartment of Medicine (Oncology), School of Medicine, Stanford University, 875 Blake Wilbur Drive, Stanford, 94305, California, USA.
Carlos D BustamanteDepartment of Biomedical Data Science, School of Medicine, Stanford University, 1265 Welch Road, Stanford, California, 94305, USA.ORCID http://orcid.org/0000-0002-2884-4286

Funding

Clinically Relevant Genome Variation DatabaseU01HG007436 · NHGRI · STANFORD UNIVERSITY · PI BUSTAMANTE, CARLOS DANIEL, PLON, SHARON E. · 2013 to 2016
$10.5M
UCSF-Stanford Center of Excellence in Regulatory Science and InnovationU01FD004979 · FDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ALTMAN, RUSS BIAGIO, GIACOMINI, KATHLEEN M · 2014 to 2016
$5.4M
FDA HHS U01 FD004979National Human Genome Research Institute U01 HG007436-04NHGRI NIH HHS U01 HG007436U.S. Food and Drug Administration U01 FD004979
6 · The paper itself

Abstract

backgroundOrganizations that issue guidance on breast cancer recommend the use of immunohistochemistry (IHC) for providing appropriate and precise care. However, little focus has been directed to the identification of maximum allowable turnaround times for IHC, which is necessary given the diversity of hospital settings in the world. Much less effort has been committed to the development of digital tools that allow hospital administrators to monitor service utilization histories of their patients.

methodsIn this retrospective cohort study, we reviewed electronic and paper medical records of all suspected breast cancer patients treated at one secondary-care hospital of the Mexican Institute of Social Security (IMSS), located in western Mexico. We then followed three years of medical history of those patients with IHC testing.

resultsIn 2014, there were 402 breast cancer patients, of which 30 (7.4% of total) were tested for some IHC biomarker (ER, PR, HER2). The subtyping allowed doctors to adjust (56.7%) or confirm (43.3%) the initial therapeutic regimen. The average turnaround time was 56 days. Opportune IHC testing was found to be beneficial when it was available before or during the first rounds of chemotherapy.

conclusionsThe use of data mining tools applied to health record data revealed that there is an association between timely immunohistochemistry and improved outcomes in breast cancer patients. Based on this finding, inclusion of turnaround time in clinical guidelines is recommended. As much of the health data in the country becomes digitized, our visualization tools allow a digital dashboard of the hospital service utilization histories.

Indexed as

Data MiningAdultAgedAntineoplastic AgentsBreast NeoplasmsElectronic Health RecordsFemaleHumansImmunophenotypingMexicoMiddle AgedPrecision MedicineRetrospective StudiesTreatment OutcomeAntineoplastic AgentsBreast neoplasmsClinical codingData miningImmunohistochemistryMedical recordsMexicoTumor biomarkers

Identifiers

PMID30261931
PMCPMC6161369

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.